Filters
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
Academic, open label, randomized trial: G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome. GA trial is registered under EudraCT#: 2013-001639-38....
Hematology
- 2022 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy.
Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy - conference abstract....
Hematology
- 2023 •
- O
Rok uplatnění
O - Ostatní výsledky
Sequences for determination of the transcription activity and expression levels of the target gene for 5-azacitidine treatment
Oligonucleotide sequences, designed to measure the relationship between abundance and localization of key molecular factors in samples of tumor cells towards improvement of the diagnosis, prognosis and estimate the potential effectiveness of treatmen...
EB - Genetika a molekulární biologie
- 2012 •
- Fuzit •
- Link
Rok uplatnění
Fuzit - Užitný vzor
Výsledek na webu
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
prognosis, even after treatment with a hypomethylating agent. Azacitidine added of age or older, or both to azacitidine plus either venetoclax or placebo. All patients received a standard dose of azacitidine (75 mg per squ...
Hematology
- 2020 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Report of University Hospital Ostrava to the clinical trial protokol No: 2014-3634
Randomized, Two-Way, Crossover Study to Assess the Comparative Bioavailability of Subcutaneous Azacitidine Compared With Subcutaneous Vidaza® in Patients With Myelodysplastic Syndrome (MDS) on Azacitidine Therapy....
FD - Onkologie a hematologie
- 2016 •
- Vsouhrn
Rok uplatnění
Vsouhrn - Souhrnná výzkumná zpráva
Report from the latest analyzes of Vidaza (azacitidine) and Revlimid (lenalidomide) therapy in patients with myelodysplastic syndrome in the Czech Republic: data from MyDyS registry
This paper deals with recent analyzes of Vidaza (azacitidine) and Revlimid (lenalidomide) therapy in patients with myelodysplastic syndrome in the Czech Republic using data from MyDyS registry......
Hematology
- 2019 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
Research Report University Hospital clinical trial AZA-MDS-003
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and...
FD - Onkologie a hematologie
- 2014 •
- Vsouhrn
Rok uplatnění
Vsouhrn - Souhrnná výzkumná zpráva
Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms
Azacitidine (AZA) is a hypomethylating drug used to treat disorders associated with myelodysplasia and related neoplasms. Our data indicate that AZA treatment failure is associated with the up-regulation of ribosomal genes/pathways that are ...
FD - Onkologie a hematologie
- 2016 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia
with azacitidine, it leads to prolonged overall survival and rapid, durable remissions in combination with oral azacitidine (CC-486) as maintenance therapy in patients in complete......
Oncology
- 2022 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity
Epigenetic 5-azacitidine (AZA) therapy of high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) represents a promising, albeit not fully understood, approach. Hematopoietic transcription factor PU.1 is dynamically re...
FD - Onkologie a hematologie
- 2012 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
- 1 - 10 out of 36